Want to see INIS full AI Analyst Report?
Top Page
International Isotopes
(OTC:INIS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.06
▼(-3.33% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily held down by weak financial performance (sharp TTM losses, high leverage, and negative/volatile cash flow) and a technically weak price trend (trading below key moving averages with negative MACD). Corporate actions modestly offset risk by improving capital flexibility and expanding the product/technology base, but valuation metrics provided do not add meaningful support.
Positive Factors
Exposure to Specialized Isotope Markets
The company serves specialized markets requiring isotope expertise, controlled-material handling, and regulatory compliance. These capabilities can create operational barriers and support durable customer relevance across medical and industrial applications.
Negative Factors
Severe Profitability Deterioration
Deep operating losses and an unusually large net loss weaken internal funding capacity and raise concerns about earnings quality. Unless profitability recovers, the company may remain dependent on financing and have limited flexibility to invest in growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Exposure to Specialized Isotope Markets
The company serves specialized markets requiring isotope expertise, controlled-material handling, and regulatory compliance. These capabilities can create operational barriers and support durable customer relevance across medical and industrial applications.
Read all positive factors
International Isotopes (INIS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.17M
Dividend YieldN/A
Average Volume (3M)97.60K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-23.73%
EPS Growth-2800.00%
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1723.63
Shares Outstanding529,154,200
10 Day Avg. Volume65,048
30 Day Avg. Volume97,599
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.74
Price to Sales (P/S)2.47
P/FCF Ratio375.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
International Isotopes Business Overview & Revenue Model
Company Description
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radi...
How the Company Makes Money
INIS generates revenue primarily by selling isotopes/radiochemical products and by charging service fees for isotope-related processing and handling work. Key revenue streams generally fall into: (1) Product sales: revenue from supplying isotopes ...
International Isotopes Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.23M | 13.07M | 13.90M | 12.27M | 11.18M | 9.66M |
| Gross Profit | 3.56M | 3.21M | 8.65M | 7.38M | 6.29M | 5.74M |
| EBITDA | -2.14M | -166.28K | 804.17K | -163.13K | 1.31M | 631.12K |
| Net Income | -908.00B | -908.00K | 8.57K | -869.02K | -310.70K | -2.38M |
Balance Sheet | ||||||
| Total Assets | 16.65M | 17.84M | 17.16M | 16.91M | 16.24M | 16.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.20M | 1.70T | 1.95M | 2.69M | 2.38M | 474.85K |
| Total Debt | 9.21M | 4.84T | 8.36M | 8.34M | 4.05M | 4.46M |
| Total Liabilities | 14.75M | 14.14M | 12.81M | 12.87M | 11.90M | 13.60M |
| Stockholders Equity | 1.89M | 3.69M | 4.35M | 4.04M | 4.34M | 2.73M |
Cash Flow | ||||||
| Free Cash Flow | -925.24K | 86.01K | -82.43K | 433.53K | -1.62M | -367.39K |
| Operating Cash Flow | -376.28K | 620.16K | 638.78K | 582.59K | -1.50M | -161.91K |
| Investing Cash Flow | -548.96K | -534.15K | -685.22K | -149.06K | 3.88M | -205.47K |
| Financing Cash Flow | 319.05K | -275.86K | -145.23K | -80.50K | -472.00K | -78.70K |
International Isotopes Technical Analysis
Negative
0.06
Price Trends
0.07
Negative
0.07
Negative
0.07
Negative
Market Momentum
>-0.01
Positive
45.26
Neutral
71.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INIS, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.26 is Neutral, neither overbought nor oversold. The STOCH value of 71.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INIS.
International Isotopes Risk Analysis
International Isotopes disclosed 23 risk factors in its most recent earnings report. International Isotopes reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
International Isotopes Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $29.87M | -5.38 | -14.03% | ― | -21.12% | -109.07% | |
52 Neutral | $63.84M | -3.76 | -87.28% | ― | -96.30% | 35.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $51.54M | -2.77 | -21.10% | ― | 489.78% | 45.39% | |
47 Neutral | $25.55M | -0.55 | -148.91% | ― | -18.24% | -2264.65% | |
44 Neutral | $32.17M | ― | -5.69% | ― | -23.73% | -2800.00% | |
41 Neutral | $379.73K | >-0.01 | -453.74% | ― | ― | ― |
* Healthcare Sector Average
INIS
International Isotopes
0.06
-0.03
-33.33%
TLPH
Talphera
1.20
0.77
177.78%
PRPH
Prophase Labs
0.03
-3.31
-99.10%
RMTI
Rockwell Med
7.49
-3.01
-28.71%
SCYX
SCYNEXIS
5.09
-1.33
-20.72%
AYTU
Aytu BioScience
2.36
0.16
7.27%
International Isotopes Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Radnostix Enhances Capital Flexibility with Note Amendments
Positive
Jul 1, 2026
On June 25, 2026, Radnostix completed the acquisition of Lucerno Dynamics’ Lara System platform and Ellexa Explorer software, including all associated IP, regulatory approvals and hardware, in a deal initially valued at $900,000 split betwee...
Private Placements and FinancingRegulatory Filings and Compliance
Radnostix Extends Series C Preferred Stock Maturity Date
Positive
May 20, 2026
On May 14, 2026, Radnostix, Inc. obtained approval from a majority of holders of its Series C Convertible Redeemable Preferred Stock to modify the security’s terms by extending its maturity date by one year to Feb. 28, 2028, while leaving al...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.